Drug profile

The FDA adverse-event record for Toceranib Phosphate

1,093 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Toceranib Phosphate. See the species affected, top reactions, and outcomes below.

1,093
adverse-event reports
12.6%
death-coded share
Dog
most-reported species
189
Diarrhoea - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
1,093
Total Reports
138
Deaths Reported
12.6%
Death Rate

Active Ingredients

Toceranib Phosphate

Administration Routes

OralUnknownTopicalOtherSubconjunctivalRectalOphthalmic

Species Affected

Dog 891
Cat 97
Unknown 79
Human 25
Other Rodents 1

Most Affected Breeds

Retriever - Labrador 105
Unknown 104
Dog (unknown) 78
Retriever - Golden 48
Domestic Shorthair 47
Boxer (German Boxer) 41
Mixed (Dog) 39
Terrier - Bull - American Pit 31
Crossbred Canine/dog 30
Pug 28

Most Reported Reactions

Diarrhoea 189
Vomiting 170
Anorexia 131
Lethargy (see also Central nervous system depression in 'Neurological') 86
Lack of efficacy - NOS 85
Anaemia NOS 83
Lameness 82
Weight loss 80
Death by euthanasia 78
Neutropenia 76
Leucopenia NOS 72
Elevated serum alkaline phosphatase (SAP) 71

Outcome Breakdown

Ongoing
506 (55.7%)
Outcome Unknown
161 (17.7%)
Recovered/Normal
102 (11.2%)
Died
80 (8.8%)
Euthanized
59 (6.5%)

Toceranib Phosphate Adverse Event Insights

1,093 reports name Toceranib Phosphate; 138 recorded a death outcome (12.6% of reported events, not a population-level mortality rate). Active ingredient: Toceranib Phosphate. Administration routes: Oral, Unknown, Topical, Other.

By species: Dog (891 reports), Cat (97 reports), Unknown (79 reports). By breed: Retriever - Labrador (105), Unknown (104), Dog (unknown) (78).

Leading clinical signs: Diarrhoea (189), Vomiting (170), Anorexia (131), Lethargy (see also Central nervous system depression in 'Neurological') (86). Outcome, 908 coded reports: Ongoing leads at 55.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.